Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

被引：1

作者：

Raje, Noopur S. ^{[1
,7
]}

Cohen, Adam D. ^{[2
]}

Patel, Krina K. ^{[3
]}

van de Donk, Niels W. C. J. ^{[4
]}

Richter, Joshua ^{[5
]}

San-Miguel, Jesus ^{[6
]}

机构：

[1] Massachusetts Gen Hosp, Div Hematol Oncol, Canc Ctr, Boston, MA USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX USA

[4] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[5] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[6] Univ Navarra, Canc Ctr Clin, CIMA, IDISNA,CIBERONC, Pamplona, Spain

[7] Massachusetts Gen Hosp, Ctr Multiple Myeloma, Canc Ctr, Boston, MA 02114 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷 / 06期

关键词：

Lymphoma; Myeloma Leukemia; 24; 6; rights Bispecific antibody; Chimeric antigen receptor T cells; Multiple myeloma; T-cell engager; T-CELL THERAPY; MULTIPLE-MYELOMA; RISK; INFECTION; EFFICACY; SAFETY;

D O I：

10.1016/j.clml.2024.03.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The 20th annual IMS meeting dedicated a session to the practical aspects regarding T-cell redirected therapies, specifically chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies/T-cell engagers (bsAbs/TCEs), an increasing number of which have been introduced recently into the relapsed/refractory MM (RRMM) treatment landscape. This article summarizes the discussions and key take-home messages from this session. Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.

引用

页码：350 / 357

页数：8

共 35 条

[21] Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Lin, Yi
Qiu, Lugui
Usmani, Saad
Joo, Chng Wee
Costa, Luciano
Derman, Benjamin
Du, Juan
Einsele, Hermann
de Larrea, Carlos Fernandez
Hajek, Roman
Ho, P. Joy
Kastritis, Efstathios
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Mikhael, Joseph
Moreau, Philippe
Nagarajan, Chandramouli
Nooka, Ajay
O'Dwyer, Michael
Schjesvold, Fredrik
Sidana, Surbhi
van de Donk, Niels W. C. J.
Weisel, Katja
Zweegman, Sonja
Raje, Noopur
Otero, Paula Rodriguez
Anderson Jr, Larry D.
Kumar, Shaji
Martin, Tom
LANCET ONCOLOGY, 2024, 25 (08) : e374 - e387
[22] Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology
Gridelli, Cesare
Ascierto, Paolo A.
Barberis, Massimo C. P.
Felip, Enriqueta
Garon, Edward B.
O'brien, Mary
Senan, Suresh
Casaluce, Francesca
Sgambato, Assunta
Papadimitrakopoulou, Vali
De Marinis, Filippo
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (12) : 1479 - 1489
[23] Congress report: 49th Annual Meeting of the American Society of Haematology, Georgia World Congress Center, December 8-11 2007, Atlanta, Georgia
Schmidt, S.
Steurer, M.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2008, 1 (02) : 103 - 109
[24] The Promise of a Cancer-Free World: Where Are We? The Presidential Address from the 35th Annual Meeting of the American Society of Preventive Oncology (ASPO)
Paskett, Electra D.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (09) : 1982 - 1989
[25] Circulating and Disseminated Tumor Cells in Breast Carcinoma Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Banys-Paluchowski, Malgorzata
Fehm, Tanja
Janni, Wolfgang
Solomayer, Erich-Franz
Hartkopf, Andreas
GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1320 - 1327
[26] Orlando Magic: report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA
Mazzarella, Luca
ECANCERMEDICALSCIENCE, 2016, 10
[27] Tick-borne encephalitis - a notifiable disease Report of the 15th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE)
Kunze, Ursula
TICKS AND TICK-BORNE DISEASES, 2013, 4 (05) : 363 - 365
[28] Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health
Psomas, Christina
Kinloch, Sabine
Sabin, Caroline
Soriano, Vicente
Solas, Caroline
Orkin, Chloe
Bernardino, Jose
Curran, Adrian
Routy, Jean-Pierre
Enel, Patricia
Philibert, Patrick
Lafeuillade, Alain
JOURNAL OF VIRUS ERADICATION, 2018, 4 (03) : 196 - 207
[29] Tick-borne encephalitis-still on the map Report of the 18th annual meeting of the international scientific working group on tick-borne encephalitis (ISW-TBE)
Kunze, Ursula
TICKS AND TICK-BORNE DISEASES, 2016, 7 (05) : 911 - 914
[30] Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies
Borte, Michael
Anderson-Smits, Colin
Hermann, Corinna
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 : 7 - 8

← 1 2 3 4 →